Jinwon Life Sciences "Oral COVID-19 Treatment Confirmed to Suppress Infection Symptoms Even Against Variants"

[Asia Economy Reporter Kim Ji-hee] GeneOne Life Science announced on the 30th that 'GLS-1027,' an oral COVID-19 treatment under development, showed effectiveness against the South African variant of the virus.

According to GeneOne Life Science, GLS-1027 induced a dose-dependent reduction in pneumonia symptom markers in a hamster attack infection model that causes severe COVID-19 pneumonia. It was also confirmed that virus-induced syncytia and cellular atypia in lung tissue decreased. The company explained that this therapeutic effect was similarly observed in the South African variant.

A GeneOne Life Science official stated, "This research result demonstrates effective prevention of IL-17 secretion and Th17 pathological features, which are phenomena of the cytokine storm caused by COVID-19 infection."

GLS-1027 has received FDA clinical phase 2 approval and clinical trials have begun in the United States and Puerto Rico. Clinical trials are planned to start in North Macedonia and Bulgaria, and in February, an application for clinical approval was submitted to the Korean Ministry of Food and Drug Safety, which is currently under review. The company expects that newly confirmed patients taking GLS-1027 capsules during self-quarantine will be prevented from hospitalization, and those hospitalized with moderate symptoms will be prevented from worsening to severe conditions.

Park Young-geun, CEO of GeneOne Life Science, said, "The research results showed how effectively GLS-1027 can address severe symptoms caused by the virus in COVID-19 treatment. In particular, it is significant that GLS-1027 showed effectiveness regardless of variant viruses, as it is expected that variants resistant to vaccines will emerge in the future, as well as existing variant viruses."

This content was produced with the assistance of AI translation services.